Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
CTLA4 1493 SIROLIMUS CHEMBL413 NCI 11698435, 7982907
CTLA4 1493 MELPHALAN CHEMBL852 PharmGKB
CTLA4 1493 IPILIMUMAB CHEMBL1789844 inhibitor, antibody GuideToPharmacologyInteractions, DrugBank, ChemblInteractions, TTD, CancerCommons, MyCancerGenome, TALC, ClearityFoundationClinicalTrial, TdgClinicalTrial 18049334
CTLA4 1493 TREMELIMUMAB CHEMBL2108658 inhibitor, antibody TALC, MyCancerGenome, TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TTD
CTLA4 1493 ATPGAMMAS CHEMBL131890 NCI 7732566
CTLA4 1493 RIZATRIPTAN CHEMBL905 NCI 11159548
CTLA4 1493 PREDNISONE CHEMBL635 PharmGKB
CTLA4 1493 BLEOMYCIN (CHEMBL3039590) CHEMBL3039590 NCI 11489978
CTLA4 1493 METHIMAZOLE CHEMBL1515 NCI 15504312
CTLA4 1493 PHORBOL MYRISTATE ACETATE CHEMBL279115 NCI 10777098, 8946678
CTLA4 1493 WORTMANNIN CHEMBL428496 NCI 10464177
CTLA4 1493 ANTIBIOTIC CHEMBL606111 NCI 10030847
CTLA4 1493 THALIDOMIDE CHEMBL468 NCI 10823791
CTLA4 1493 ATEZOLIZUMAB CHEMBL3707227 CIViC 25428504
CTLA4 1493 ALCOHOL CHEMBL545 NCI 11025487

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
CTLA4 rs231775 G glatiramer acetate efficacy no Allele G is not associated with decreased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele A. 22111603 827823561
CTLA4 rs3087243 A adalimumab efficacy no Allele A is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G. 23007924 981417489
CTLA4 rs16840252 T tacrolimus metabolism/PK no This study was attempting to validate reported variants and tacrolimus trough concentration in a large population of African American and European American kidney transplant patients. This SNP is a proxy for rs4553808. Authors described association as suggestive in the AA population but it did not survive multiple testing correction and the authors did not state which allele was the associated allele. Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C. 29318894 1449162751
CTLA4 rs4553808 AA tacrolimus metabolism/PK yes This association was significant in CYP3A5 expressors but the opposite association was seen in CYP3A5 expressers. The time of measurement was 30 days after transplantation. Day 7 and day 90 after transplantation did not show a significant association. Genotype AA is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG. 28112181 1448613196
CTLA4 rs4553808 AG + GG tacrolimus metabolism/PK yes This association was significant in CYP3A5 nonexpressors but the opposite association was seen in CYP3A5 expressers. The time of measurement was 30 days after transplantation. Day 7 and day 90 after transplantation did not show a significant association. Genotypes AG + GG is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotype AA. 28112181 1448613188